CAPR vs. APLS, XENE, AMRX, MIRM, ARWR, NAMS, KNSA, GMTX, LGND, and HRMY
Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), NewAmsterdam Pharma (NAMS), Kiniksa Pharmaceuticals (KNSA), Gemini Therapeutics (GMTX), Ligand Pharmaceuticals (LGND), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical preparations" industry.
Capricor Therapeutics vs. Its Competitors
Capricor Therapeutics (NASDAQ:CAPR) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings.
Capricor Therapeutics received 11 more outperform votes than Apellis Pharmaceuticals when rated by MarketBeat users. However, 66.29% of users gave Apellis Pharmaceuticals an outperform vote while only 63.80% of users gave Capricor Therapeutics an outperform vote.
Capricor Therapeutics has higher earnings, but lower revenue than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.
21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 10.5% of Capricor Therapeutics shares are held by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Capricor Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.
Capricor Therapeutics presently has a consensus target price of $35.50, suggesting a potential upside of 154.66%. Apellis Pharmaceuticals has a consensus target price of $40.05, suggesting a potential upside of 107.96%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Capricor Therapeutics is more favorable than Apellis Pharmaceuticals.
Apellis Pharmaceuticals has a net margin of -34.97% compared to Capricor Therapeutics' net margin of -146.86%. Apellis Pharmaceuticals' return on equity of -103.11% beat Capricor Therapeutics' return on equity.
In the previous week, Capricor Therapeutics had 9 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 22 mentions for Capricor Therapeutics and 13 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 1.10 beat Capricor Therapeutics' score of 0.53 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.
Summary
Apellis Pharmaceuticals beats Capricor Therapeutics on 10 of the 19 factors compared between the two stocks.
Get Capricor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Capricor Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CAPR) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy CAPR Stock Free CAPR Stock Alerts